VanEck Vectors Biotech ETF (NASDAQ:BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVISÂ® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund’s benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
- YTD Daily Total Return: 13.49%
- Expense Ratio: 0.35%
- Annual Dividend Yield: 0.30%
- Three-Month Average Daily Volume: 15,785
- Assets Under Management: $574.36 million
- Inception Date: Dec. 20, 2011
- Issuer: VanEck
- 13.49% YTD Daily Total Return
- 22.84% 1-Year Daily Total Return
- 18.32% 3-Year Daily Total Return
BBH tracks the MVIS US Listed Biotech 25 Index, an index of companies involved in the development and production, sales, and marketing of therapies based on genetic analysis and diagnostic equipment. The fund is highly concentrated in a few names, with the top 10 of its 24 holdings accounting for more than 60% of all invested assets.
Top 10 Holdings (54.41% of Total Assets)
|Gilead Sciences Inc||GILD||5.41%|
|Regeneron Pharmaceuticals Inc||REGN||5.22%|
|Alexion Pharmaceuticals Inc||ALXN||5.00%|
|IQVIA Holdings Inc||IQV||4.94%|
|Charles River Laboratories International Inc||CRL||4.64%|
|Vertex Pharmaceuticals Inc||VRTX||4.60%|
|Exact Sciences Corp||EXAS||4.58%|
Therefore, VanEck Vectors Biotech ETF is best for investors who are interested of holding top biotech stocks.